By Ben Butkus

MicroParticle Proteomics said last week that it has exclusively licensed a blood-based biomarker from the University of Virginia Patent Foundation that could serve as the basis for diagnostic and prognostic tests for cardiovascular disease and ischemic heart failure.

The biomarker was discovered by former UVA researcher and company co-founder Klaus Ley using a proteomics platform that he also developed while at the university and upon which MPP was founded.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.